Juan J. Marugan

发表

Figure 3, Schematic of cAMP competitive immunoassay

Steve Titus, Wenwei Huang, Juan J. Marugan, 2011 .

Scheme 1, General strategy for modification in the functional core

Wenwei Huang, Juan J. Marugan, Noel Southall, 2011 .

Table 2, Assay protocol for the TSHR and parental cell lines in 1536 well format

Steve Titus, Wenwei Huang, Juan J. Marugan, 2011 .

Table 5, Comparison of probe to prior art

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 4, Profiling of the probe, ML246, in the PDSP comprehensive panel

Steve Titus, Juan J. Marugan, Wei Zheng, 2010 .

Figure 4, Performance of primary qHTS screen

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 1, Assay protocols and data deposited into PubChem

Wenwei Huang, Juan J. Marugan, Wei Zheng, 2011 .

Figure 4, High-throughput screen

Steve Titus, Wenwei Huang, Juan J. Marugan, 2011 .

Figure 1, Overview of screening process

Steve Titus, Juan J. Marugan, Noel Southall, 2010 .

Figure 4, Analog design for SAR of CID 284708

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Scheme 1, Synthetic route toward ML223

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 2, Probe and analog submissions to the MLSMR (Evotec) for Identification of Compounds that Reduce PNC Prevalence

Steve Titus, Juan J. Marugan, Noel Southall, 2010 .

Table 7, Summary of data in PubChem

Steve Titus, Wenwei Huang, Juan J. Marugan, 2010 .

Table 6, Comparison of ML247 to prior art

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Figure 8, Structure and selected physical properties of the qHTS hits and their performance in the primary and follow-up assays

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 3, BellBrook Labs Proliferation and Migration Data for Key Compounds

Steve Titus, Juan J. Marugan, Wei Zheng, 2010 .

Scheme 2, Synthesis of CID 60859

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 1, Summary of Key Properties for ML246

Steve Titus, Juan J. Marugan, Noel Southall, 2010 .

Table 13, Comparison of ADME profile for hit 1 and ML290

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Figure 7, Work flow for the identification of hits as agonists of the relaxin receptor 1 (RXFP1) in the qHTS screening campaign

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Scheme 2, Analog synthesis

Steve Titus, Wenwei Huang, Juan J. Marugan, 2011 .

Scheme 7, Additional modifications at the 2 position

Wenwei Huang, Juan J. Marugan, Noel Southall, 2011 .

Scheme 1, Synthetic route to ML247

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Figure 2, Schematic drawing of the AlphaScreen assay for the RUNX1::CBFβ-SMMHC interaction

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 2, Typical protocol of primary and secondary assays

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Scheme 1, Convergent and scalable synthetic routes to ML290

Juan J. Marugan, Noel Southall, Wei Zheng, 2013 .

Table 1, Screen Quest™ Fluor-8 of D2 Ca2+ qHTS assay protocol

Steve Titus, Juan J. Marugan, Noel Southall, 2013 .

Original articleNovel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin

Juan J. Marugan, B. Tomczuk, J. Marugan, 2006 .

Induction and Reversal of Myotonic Dystrophy Type 1 Pre-mRNA Splicing Defects by Small Molecules

Juan J. Marugan, Noel Southall, Wei Zheng, 2013, Nature Communications.

A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp

Juan J. Marugan, Noel Southall, Christopher P. Austin, 2014, PloS one.